{"hands_on_practices": [{"introduction": "The decision between cell survival and apoptosis is finely balanced by the interactions among BCL-2 family proteins. This exercise invites you to apply fundamental principles of biochemical equilibrium to a critical interaction: the sequestration of the pro-apoptotic protein BIM by the anti-apoptotic protein BCL-XL. By calculating the fraction of bound BIM under specific conditions [@problem_id:2949690], you will gain a quantitative appreciation for how anti-apoptotic proteins can \"buffer\" death signals and control the threshold for initiating mitochondrial outer membrane permeabilization.", "problem": "In the intrinsic (mitochondrial) apoptosis pathway, the B-cell lymphoma-extra large (BCL-XL) protein sequesters the BCL-2 interacting mediator of cell death (BIM) through its Bcl-2 homology 3 (BH3) domain, limiting BIM’s availability to directly activate BCL-2–associated X protein (BAX). Consider a single-site equilibrium binding interaction between BIM and BCL-XL characterized by the dissociation constant $K_{d}$ defined by the law of mass action as $K_{d}=\\frac{[BIM]_{\\text{free}}\\,[BCL\\text{-}XL]_{\\text{free}}}{[BIM{\\cdot}BCL\\text{-}XL]}$. You are given $K_{d}=1\\,\\mathrm{nM}$ for BIM BH3 binding to BCL-XL, total BIM concentration $[BIM]_{\\text{tot}}=5\\,\\mathrm{nM}$, and total BCL-XL concentration $[BCL\\text{-}XL]_{\\text{tot}}=10\\,\\mathrm{nM}$. Using conservation of mass and the definition of $K_{d}$ for a $1{:}1$ interaction at equilibrium, compute the fraction of total BIM that is bound to BCL-XL. Express the fraction as a decimal number between $0$ and $1$, and round your answer to $4$ significant figures. Then, based on your quantitative result and standard principles of BH3-only regulation of anti-apoptotic BCL-2 family proteins, briefly explain whether BIM availability to activate BAX is likely to be high or low under these conditions (qualitative discussion only; do not include this discussion in the final numerical answer).", "solution": "The problem is valid as it is scientifically grounded, well-posed, and contains sufficient information for a unique solution. We will proceed by applying the law of mass action and principles of conservation of mass to the specified single-site binding equilibrium.\n\nLet the total concentration of BIM be $[BIM]_{\\text{tot}}$ and the total concentration of BCL-XL be $[BCL\\text{-}XL]_{\\text{tot}}$. Let $x$ represent the equilibrium concentration of the bound complex, $[BIM{\\cdot}BCL\\text{-}XL}]$.\n\nThe given parameters are:\n$[BIM]_{\\text{tot}} = 5\\,\\mathrm{nM}$\n$[BCL\\text{-}XL]_{\\text{tot}} = 10\\,\\mathrm{nM}$\n$K_{d} = 1\\,\\mathrm{nM}$\n\nThe conservation of mass for each species dictates:\n$[BIM]_{\\text{tot}} = [BIM]_{\\text{free}} + [BIM{\\cdot}BCL\\text{-}XL}]$\n$[BCL\\text{-}XL]_{\\text{tot}} = [BCL\\text{-}XL]_{\\text{free}} + [BIM{\\cdot}BCL\\text{-}XL}]$\n\nFrom these relations, we can express the free concentrations in terms of the total concentrations and the concentration of the complex, $x$:\n$[BIM]_{\\text{free}} = [BIM]_{\\text{tot}} - x$\n$[BCL\\text{-}XL]_{\\text{free}} = [BCL\\text{-}XL]_{\\text{tot}} - x$\n\nThe dissociation constant, $K_{d}$, is defined by the law of mass action as:\n$$K_{d} = \\frac{[BIM]_{\\text{free}}\\,[BCL\\text{-}XL]_{\\text{free}}}{[BIM{\\cdot}BCL\\text{-}XL]}$$\n\nSubstituting the expressions for the free concentrations and the complex concentration $x$ into the $K_{d}$ equation yields:\n$$K_{d} = \\frac{([BIM]_{\\text{tot}} - x)([BCL\\text{-}XL]_{\\text{tot}} - x)}{x}$$\n\nThis equation can be rearranged into a standard quadratic form, $ax^2 + bx + c = 0$.\n$K_{d} \\cdot x = ([BIM]_{\\text{tot}} - x)([BCL\\text{-}XL]_{\\text{tot}} - x)$\n$K_{d} \\cdot x = [BIM]_{\\text{tot}}[BCL\\text{-}XL]_{\\text{tot}} - [BIM]_{\\text{tot}}x - [BCL\\text{-}XL]_{\\text{tot}}x + x^2$\n$$x^2 - ([BIM]_{\\text{tot}} + [BCL\\text{-}XL]_{\\text{tot}} + K_{d})x + [BIM]_{\\text{tot}}[BCL\\text{-}XL]_{\\text{tot}} = 0$$\n\nNow, we substitute the numerical values provided in the problem statement into this quadratic equation. All concentrations are in units of $\\mathrm{nM}$.\n$x^2 - (5 + 10 + 1)x + (5)(10) = 0$\n$$x^2 - 16x + 50 = 0$$\n\nWe solve for $x$ using the quadratic formula, $x = \\frac{-b \\pm \\sqrt{b^2 - 4ac}}{2a}$, where $a=1$, $b=-16$, and $c=50$.\n$$x = \\frac{16 \\pm \\sqrt{(-16)^2 - 4(1)(50)}}{2(1)}$$\n$$x = \\frac{16 \\pm \\sqrt{256 - 200}}{2}$$\n$$x = \\frac{16 \\pm \\sqrt{56}}{2}$$\n$$x = \\frac{16 \\pm 2\\sqrt{14}}{2}$$\n$$x = 8 \\pm \\sqrt{14}$$\n\nThis gives two possible mathematical solutions for $x$:\n$x_1 = 8 + \\sqrt{14} \\approx 8 + 3.7417 = 11.7417\\,\\mathrm{nM}$\n$x_2 = 8 - \\sqrt{14} \\approx 8 - 3.7417 = 4.2583\\,\\mathrm{nM}$\n\nWe must select the physically meaningful solution. The concentration of the complex, $x$, cannot exceed the total concentration of either of the binding partners. The limiting reactant in this system is BIM, with a total concentration of $[BIM]_{\\text{tot}} = 5\\,\\mathrm{nM}$. Therefore, the physically valid solution must satisfy the condition $0 \\le x \\le 5\\,\\mathrm{nM}$.\nThe first root, $x_1 \\approx 11.7417\\,\\mathrm{nM}$, violates this condition and is therefore discarded as physically impossible.\nThe second root, $x_2 \\approx 4.2583\\,\\mathrm{nM}$, satisfies this condition and is the correct equilibrium concentration of the $[BIM{\\cdot}BCL\\text{-}XL}]$ complex.\nSo, $x = 8 - \\sqrt{14}\\,\\mathrm{nM}$.\n\nThe problem requires the calculation of the fraction of total BIM that is bound to BCL-XL. This fraction is given by the ratio of the bound BIM concentration to the total BIM concentration:\n$$\\text{Fraction bound} = \\frac{[BIM{\\cdot}BCL\\text{-}XL}]}{[BIM]_{\\text{tot}}} = \\frac{x}{[BIM]_{\\text{tot}}}$$\nSubstituting the values:\n$$\\text{Fraction bound} = \\frac{8 - \\sqrt{14}}{5}$$\nNumerically, this value is:\n$$\\text{Fraction bound} \\approx \\frac{4.2583426}{5} \\approx 0.8516685$$\n\nRounding the result to $4$ significant figures, we get $0.8517$.\n\nFinally, we are asked to comment on the availability of BIM to activate BAX. The calculation shows that the fraction of bound BIM is approximately $0.8517$, which means that $85.17\\%$ of the total BIM is sequestered by BCL-XL. Consequently, only about $1 - 0.8517 = 0.1483$, or $14.83\\%$, of the total BIM is free to potentially activate BAX. Given that the vast majority of BIM is in complex with the anti-apoptotic protein BCL-XL, the availability of BIM to activate the pro-apoptotic effector protein BAX is likely to be low under these conditions. This illustrates the potent inhibitory capacity of BCL-XL when its concentration exceeds that of BIM and the binding affinity is high (low $K_{d}$).", "answer": "$$\\boxed{0.8517}$$", "id": "2949690"}, {"introduction": "Observing cytochrome $c$ release is a hallmark of the intrinsic pathway, but it is not definitive proof of BAX/BAK-mediated mitochondrial outer membrane permeabilization (MOMP). This problem challenges you to think critically about experimental design and the logic of causal inference in cell biology [@problem_id:2949692]. By evaluating different control strategies, you will understand why genetic tools, such as BAX/BAK double knockout cell lines, are the gold standard for attributing a biological outcome to a specific molecular event, distinguishing it from alternative pathways or experimental artifacts.", "problem": "A research group studies a novel B-cell lymphoma 2 (BCL-2) homology 3 (BH3)-mimetic compound that induces cytochrome c release from mitochondria, measured by immunoblotting of cytosolic fractions and by single-cell immunofluorescence. They wish to attribute the cytochrome c release specifically to mitochondrial outer membrane permeabilization (MOMP) of the intrinsic apoptotic pathway. Consider the following foundational facts as the base for your reasoning: (i) in the intrinsic pathway, pro-apoptotic BCL-2 family effectors BCL-2 Associated X (BAX) and BCL-2 antagonist killer (BAK) oligomerize in the outer mitochondrial membrane to form pores that cause MOMP; (ii) cytochrome c release into the cytosol triggers apoptosome assembly with apoptotic protease-activating factor 1 (Apaf-1) and initiator caspase activation; (iii) cytochrome c can, under some conditions, be released by BAX/BAK-independent processes such as opening of the mitochondrial permeability transition pore (mPTP), leading to osmotic swelling and outer membrane rupture, or by secondary plasma and organellar membrane damage downstream of caspase activity; (iv) pharmacologic agents can have off-target effects and incomplete target engagement; (v) genetic cause-and-effect logic relies on testing necessity and, when possible, sufficiency. Using these principles, decide which statements correctly justify the necessity of including BAX/BAK double knockout (DKO) controls when attributing cytochrome c release to MOMP in this system, and which statements propose a logically well-controlled experimental strategy to establish that attribution. Select all that apply.\n\nA. Because cytochrome c release can occur without MOMP via BAX/BAK-independent mechanisms, ablating BAX and BAK tests causal necessity of MOMP pores for the observed release. If cytochrome c release is abolished in BAX/BAK DKO cells and restored by re-expression of a single effector (for example, BAX), then, in logical terms, demonstrating $\\neg P \\Rightarrow \\neg R$ (necessity) and rescuing $P \\Rightarrow R$ supports that MOMP ($P$) causes the release ($R$) under the stimulus.\n\nB. Because executioner caspase-3 cleavage is synonymous with MOMP, showing caspase-3 activation after compound treatment renders BAX/BAK genetic controls unnecessary for attributing cytochrome c release to MOMP.\n\nC. Because cyclophilin D inhibitors such as cyclosporin A are fully specific for the mitochondrial permeability transition pore, showing that cytochrome c release is insensitive to cyclosporin A is sufficient to attribute the release to MOMP without any genetic manipulation of BAX or BAK.\n\nD. Because downstream caspase activity can secondarily compromise membranes and artifactually release cytochrome c, including a pan-caspase inhibitor (for example, zVAD-fmk) during the assay helps establish that the release occurs upstream of caspases; when this is combined with the loss of release in BAX/BAK DKO cells, the inference that the compound induces BAX/BAK-dependent MOMP is strongly supported.\n\nE. Because anti-apoptotic BCL-2 family proteins broadly block cell death, overexpression of BCL-2 is a more definitive control than BAX/BAK DKO for attributing cytochrome c release to MOMP.\n\nF. Because MOMP is the uniquely BAX/BAK-governed commitment step of the intrinsic pathway, genetic ablation of BAX/BAK isolates that specific node from upstream priming and downstream amplification. Pharmacologic or morphological readouts alone cannot uniquely resolve that node due to non-uniqueness of mapping $R \\Rightarrow P$ (many causes can yield the same readout $R$), so genetic controls are necessary to discriminate MOMP from alternatives such as mPTP-driven rupture.\n\nChoose the option(s) that are correct. Provide no partial credit; select all that apply.", "solution": "The problem statement poses a question of experimental design and logical inference within the field of molecular and cell biology, specifically concerning the intrinsic mitochondrial apoptosis pathway.\n\n**Step 1: Extract Givens**\n\nThe foundational facts provided are:\n(i) Pro-apoptotic BCL-2 family effectors BAX and BAK oligomerize in the outer mitochondrial membrane to form pores that cause MOMP.\n(ii) Cytochrome c release into the cytosol triggers apoptosome assembly with APAF$1$ and initiator caspase activation.\n(iii) Cytochrome c can be released by BAX/BAK-independent processes such as opening of the mPTP or by secondary plasma and organellar membrane damage downstream of caspase activity.\n(iv) Pharmacologic agents can have off-target effects and incomplete target engagement.\n(v) Genetic cause-and-effect logic relies on testing necessity and, when possible, sufficiency.\n\nThe objective is to evaluate statements that justify including BAX/BAK double knockout (DKO) controls to attribute an observed cytochrome c release specifically to BAX/BAK-dependent MOMP.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is scientifically grounded. The provided facts (i-v) are well-established principles in the study of apoptosis. The scenario—testing a novel BH$3$-mimetic compound—is a standard research context. The problem is well-posed, asking for a logical evaluation of experimental controls based on the provided principles. It is objective and does not contain any scientifically unsound or contradictory information. The terminology is precise and standard for the field. The problem is formalizable as a question of causal inference in experimental biology.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It presents a clear, logical challenge rooted in established scientific principles. I will proceed with a detailed analysis of each option.\n\n**Analysis of Options**\n\n**Option A: Because cytochrome c release can occur without MOMP via BAX/BAK-independent mechanisms, ablating BAX and BAK tests causal necessity of MOMP pores for the observed release. If cytochrome c release is abolished in BAX/BAK DKO cells and restored by re-expression of a single effector (for example, BAX), then, in logical terms, demonstrating $\\neg P \\Rightarrow \\neg R$ (necessity) and rescuing $P \\Rightarrow R$ supports that MOMP ($P$) causes the release ($R$) under the stimulus.**\n\nThis statement is correct. It correctly identifies from fact (iii) that alternative, BAX/BAK-independent pathways for cytochrome c release exist. The core principle of genetic knockout experiments is to test for necessity. If BAX/BAK are necessary for the compound to induce cytochrome c release, then their removal (in DKO cells) must abolish this effect. This corresponds to the logical formulation that if the presumed cause ($P$, BAX/BAK-dependent pore formation) is absent, the effect ($R$, cytochrome c release) must also be absent, given the stimulus. The statement also correctly describes the follow-up \"rescue\" experiment. Re-expressing BAX in DKO cells and observing a restoration of cytochrome c release upon treatment demonstrates sufficiency and strengthens the causal link, controlling for potential off-target effects of the genetic manipulation itself. The logical formalization $\\neg P \\Rightarrow \\neg R$ (necessity) and the rescue logic are standard and correctly applied here.\n**Verdict: Correct.**\n\n**Option B: Because executioner caspase-$3$ cleavage is synonymous with MOMP, showing caspase-$3$ activation after compound treatment renders BAX/BAK genetic controls unnecessary for attributing cytochrome c release to MOMP.**\n\nThis statement is fundamentally incorrect. The premise, \"executioner caspase-$3$ cleavage is synonymous with MOMP,\" is scientifically false. As stated in fact (ii), cytochrome c release (which is the direct result of MOMP) is an *upstream* event that triggers a cascade leading to caspase activation. MOMP and caspase-$3$ activation are distinct, causally linked events, not synonyms. Observing the downstream effect (caspase-$3$ activation) provides no specific information about the upstream mechanism of cytochrome c release, which, as per fact (iii), could be BAX/BAK-independent. Therefore, measuring caspase-$3$ activity does not, in any way, render the crucial BAX/BAK genetic controls unnecessary.\n**Verdict: Incorrect.**\n\n**Option C: Because cyclophilin D inhibitors such as cyclosporin A are fully specific for the mitochondrial permeability transition pore, showing that cytochrome c release is insensitive to cyclosporin A is sufficient to attribute the release to MOMP without any genetic manipulation of BAX or BAK.**\n\nThis statement is incorrect for two primary reasons. First, the premise that pharmacological inhibitors like cyclosporin A are \"fully specific\" is a dangerous oversimplification, directly opposed by the cautionary principle in fact (iv). Cyclosporin A has well-known off-target effects (e.g., calcineurin inhibition). Second, even if the inhibitor were perfect, the logic is insufficient. Showing that one alternative pathway (mPTP opening) is not involved does not logically prove that another specific pathway (BAX/BAK-dependent MOMP) is responsible. Other alternatives may exist, such as the secondary membrane damage mentioned in fact (iii). A pharmacological exclusion of one alternative is not equivalent to a positive demonstration of necessity for another, which is what the genetic knockout of BAX/BAK provides.\n**Verdict: Incorrect.**\n\n**Option D: Because downstream caspase activity can secondarily compromise membranes and artifactually release cytochrome c, including a pan-caspase inhibitor (for example, zVAD-fmk) during the assay helps establish that the release occurs upstream of caspases; when this is combined with the loss of release in BAX/BAK DKO cells, the inference that the compound induces BAX/BAK-dependent MOMP is strongly supported.**\n\nThis statement describes a logically robust experimental strategy and is correct. It correctly identifies a potential artifact: caspase-mediated secondary membrane damage leading to cytochrome c release, as mentioned in fact (iii). Using a pan-caspase inhibitor like zVAD-fmk is the standard method to control for this. If cytochrome c release persists in the presence of the inhibitor, it demonstrates that the release event is upstream of, and not dependent on, caspase activity. Combining this control with the BAX/BAK DKO experiment creates a powerful logical framework. The caspase inhibitor addresses the temporal ordering and rules out downstream artifacts, while the DKO demonstrates the necessity of the BAX/BAK machinery. Together, these two controls provide very strong evidence that the compound specifically triggers the canonical, pre-caspase, BAX/BAK-dependent MOMP.\n**Verdict: Correct.**\n\n**Option E: Because anti-apoptotic BCL-2 family proteins broadly block cell death, overexpression of BCL-2 is a more definitive control than BAX/BAK DKO for attributing cytochrome c release to MOMP.**\n\nThis statement is incorrect. It misjudges the logical roles of different controls. A BH$3$-mimetic compound is designed to inhibit anti-apoptotic proteins like BCL-$2$. Showing that BCL-$2$ overexpression can block the compound's effect would confirm that the compound acts on the BCL-$2$ family-regulated pathway, which is expected. However, it does not specifically test the role of the final pore-forming executioners, BAX and BAK. The BAX/BAK DKO experiment directly probes the necessity of these specific effector proteins for pore formation. For the question of attributing cytochrome c release to the pores formed by BAX and BAK, ablating these proteins themselves is the most direct and definitive control, not manipulating an upstream regulator like BCL-$2$. Therefore, BAX/BAK DKO is the more definitive control for this specific purpose.\n**Verdict: Incorrect.**\n\n**Option F: Because MOMP is the uniquely BAX/BAK-governed commitment step of the intrinsic pathway, genetic ablation of BAX/BAK isolates that specific node from upstream priming and downstream amplification. Pharmacologic or morphological readouts alone cannot uniquely resolve that node due to non-uniqueness of mapping $R \\Rightarrow P$ (many causes can yield the same readout $R$), so genetic controls are necessary to discriminate MOMP from alternatives such as mPTP-driven rupture.**\n\nThis statement provides a sophisticated and accurate logical justification for using genetic controls and is correct. It correctly frames BAX/BAK-dependent MOMP as a specific \"node\" in a complex signaling network. It then points out the fundamental limitation of observational data: an effect or readout ($R$, e.g., cytochrome c in the cytosol) can have multiple potential causes ($P_1$, $P_2$, ...). Inferring a specific cause ($P_1$) from the observation of the effect ($R$) is a logical fallacy known as affirming the consequent. Genetic ablation of BAX and BAK is the most rigorous method to test the necessity of this specific causal node, as it directly manipulates the system in a way that pharmacologic inhibitors or simple observation cannot. This statement perfectly articulates the epistemological superiority of genetic controls for establishing causality in this context.\n**Verdict: Correct.**", "answer": "$$\\boxed{ADF}$$", "id": "2949692"}, {"introduction": "Once MOMP occurs, the cell commits to apoptosis through a rapid, amplifying cascade of protease activation. This exercise introduces the power of mathematical modeling to describe the dynamics of this caspase cascade, from the initial activation of caspase-9 to the subsequent activation of the executioner caspase-3 [@problem_id:2949701]. By constructing a kinetic model and solving it under simplifying assumptions, you will see how a systems-level view can reveal key properties of the network, such as its switch-like behavior and the quantitative impact of inhibitors like XIAP.", "problem": "A central module of the intrinsic mitochondrial apoptosis pathway is the assembly of the apoptosome, which catalytically activates initiator caspase-9, which in turn activates effector caspase-3. The X-linked inhibitor of apoptosis protein (XIAP) binds and inhibits active caspase-9 and active caspase-3. Consider the following reaction scheme based on the Law of Mass Action for well-mixed kinetics:\n\n- Apoptosome, denoted by the concentration $a(t)$, catalyzes activation of procaspase-9 with concentration $z_{p}(t)$ into active caspase-9 with concentration $z(t)$.\n- Active caspase-9 $z(t)$ catalyzes activation of procaspase-3 with concentration $c_{p}(t)$ into active caspase-3 with concentration $c(t)$.\n- XIAP, with free concentration $x(t)$ and total concentration $x_{T}$, binds reversibly to $z(t)$ to form an inactive complex $y_{9}(t)$, and binds reversibly to $c(t)$ to form $y_{3}(t)$.\n\nLet $k_{9}$ and $k_{3}$ be the catalytic rate constants for apoptosome-mediated caspase-9 activation and caspase-9-mediated caspase-3 activation, respectively. Let $k_{\\text{on},9}$, $k_{\\text{off},9}$ and $k_{\\text{on},3}$, $k_{\\text{off},3}$ be the association and dissociation rate constants for XIAP binding to active caspase-9 and active caspase-3, respectively. Assume no other production or degradation reactions. Define the equilibrium dissociation constants $K_{9} \\equiv k_{\\text{off},9}/k_{\\text{on},9}$ and $K_{3} \\equiv k_{\\text{off},3}/k_{\\text{on},3}$.\n\n1) Using only the Law of Mass Action and mass conservation, construct the full set of ordinary differential equations for the concentrations $z_{p}(t)$, $z(t)$, $y_{9}(t)$, $c_{p}(t)$, $c(t)$, $y_{3}(t)$, and $x(t)$, with $x_{T} = x(t) + y_{9}(t) + y_{3}(t)$ and $a(t)$ treated as an externally specified input.\n\n2) Now impose the following scientifically realistic approximations over a short time window $0 \\le t \\ll T$:\n- The apoptosome concentration is constant, $a(t) = a_{0}$.\n- Procaspase pools are large compared to the activated fractions so that $z_{p}(t) \\approx z_{0}$ and $c_{p}(t) \\approx c_{0}$ over $0 \\le t \\ll T$.\n- XIAP binding equilibrates much faster than activation, and XIAP is abundant over this window so that $x(t) \\approx x_{0}$ is approximately constant and the binding reactions are at rapid pre-equilibrium.\n- Initially, there are no active caspases or XIAP complexes: $z(0) = c(0) = y_{9}(0) = y_{3}(0) = 0$.\n\nUnder these assumptions, derive a closed-form expression for the short-time free active caspase-3 concentration $c(t)$ as a function of $t$, expressed in terms of $k_{9}$, $k_{3}$, $a_{0}$, $z_{0}$, $c_{0}$, $x_{0}$, $K_{9}$, and $K_{3}$. Provide the expression for $c(t)$ only. No numerical evaluation is required, and no rounding is needed. Express the final answer as a single analytic expression.", "solution": "The problem statement has been evaluated and is deemed to be valid. It is scientifically grounded, self-contained, and well-posed. We may proceed with the solution.\n\nThe problem is divided into two parts. First, we construct the full kinetic model based on the Law of Mass Action. Second, we solve for the concentration of active caspase-$3$, denoted $c(t)$, under a set of simplifying, scientifically reasonable assumptions for short time scales.\n\n**Part 1: Construction of the Full System of Ordinary Differential Equations (ODEs)**\n\nThe system involves the following reactions:\n$1$. Procaspase-$9$ ($z_p$) activation, catalyzed by apoptosome ($a$): $z_p \\xrightarrow{k_9, a} z$\n$2$. Procaspase-$3$ ($c_p$) activation, catalyzed by active caspase-$9$ ($z$): $c_p \\xrightarrow{k_3, z} c$\n$3$. Reversible binding of XIAP ($x$) to active caspase-$9$ ($z$): $x + z \\underset{k_{\\text{off},9}}{\\stackrel{k_{\\text{on},9}}{\\rightleftharpoons}} y_9$\n$4$. Reversible binding of XIAP ($x$) to active caspase-$3$ ($c$): $x + c \\underset{k_{\\text{off},3}}{\\stackrel{k_{\\text{on},3}}{\\rightleftharpoons}} y_3$\n\nAccording to the Law of Mass Action, the rate of change for each concentration is the sum of the rates of the reactions producing it minus the sum of the rates of the reactions consuming it.\n\nThe rate of procaspase-$9$ consumption is from reaction $1$:\nRate of formation of $z$ = $k_9 a(t) z_p(t)$. This depletes $z_p$.\n$$ \\frac{dz_p(t)}{dt} = -k_9 a(t) z_p(t) $$\n\nThe rate of procaspase-$3$ consumption is from reaction $2$:\nRate of formation of $c$ = $k_3 z(t) c_p(t)$. This depletes $c_p$.\n$$ \\frac{dc_p(t)}{dt} = -k_3 z(t) c_p(t) $$\n\nThe concentration of free active caspase-$9$, $z(t)$, changes due to its production from $z_p$ and the reversible binding with $x(t)$.\n$$ \\frac{dz(t)}{dt} = k_9 a(t) z_p(t) - k_{\\text{on},9} x(t) z(t) + k_{\\text{off},9} y_9(t) $$\nNote that $z(t)$ acts as a catalyst in reaction $2$ and is not consumed in that step.\n\nThe concentration of the XIAP-caspase-$9$ complex, $y_9(t)$, changes due to the forward and reverse binding reactions.\n$$ \\frac{dy_9(t)}{dt} = k_{\\text{on},9} x(t) z(t) - k_{\\text{off},9} y_9(t) $$\n\nThe concentration of free active caspase-$3$, $c(t)$, changes due to its production from $c_p$ and the reversible binding with $x(t)$.\n$$ \\frac{dc(t)}{dt} = k_3 z(t) c_p(t) - k_{\\text{on},3} x(t) c(t) + k_{\\text{off},3} y_3(t) $$\n\nThe concentration of the XIAP-caspase-$3$ complex, $y_3(t)$, changes due to its respective binding reactions.\n$$ \\frac{dy_3(t)}{dt} = k_{\\text{on},3} x(t) c(t) - k_{\\text{off},3} y_3(t) $$\n\nThe concentration of free XIAP, $x(t)$, is depleted by binding to $z(t)$ and $c(t)$ and restored by the dissociation of the complexes $y_9(t)$ and $y_3(t)$.\n$$ \\frac{dx(t)}{dt} = -k_{\\text{on},9} x(t) z(t) + k_{\\text{off},9} y_9(t) - k_{\\text{on},3} x(t) c(t) + k_{\\text{off},3} y_3(t) $$\nThis completes the system of $7$ ODEs for the specified concentrations.\n\n**Part 2: Derivation of $c(t)$ under Simplifying Assumptions**\n\nWe are tasked with finding a closed-form expression for $c(t)$ for a short time window $0 \\le t \\ll T$ under the following assumptions:\n- $a(t) = a_0$ (constant)\n- $z_p(t) \\approx z_0$ and $c_p(t) \\approx c_0$ (large, constant procaspase pools)\n- XIAP binding reactions are at rapid pre-equilibrium, and XIAP is abundant, so $x(t) \\approx x_0$ (constant).\n- Initial conditions: $z(0) = c(0) = y_9(0) = y_3(0) = 0$.\n\nThe rapid pre-equilibrium assumption means that the binding and dissociation processes are much faster than the activation processes. Thus, the ODEs for the complexes $y_9(t)$ and $y_3(t)$ can be approximated as being equal to $0$.\nFor $y_9(t)$: $\\frac{dy_9(t)}{dt} \\approx 0 \\implies k_{\\text{on},9} x(t) z(t) \\approx k_{\\text{off},9} y_9(t)$.\nUsing the assumption $x(t) \\approx x_0$, we can solve for $y_9(t)$:\n$$ y_9(t) \\approx \\frac{k_{\\text{on},9}}{k_{\\text{off},9}} x_0 z(t) = \\frac{x_0}{K_9} z(t) $$\nwhere $K_9 = k_{\\text{off},9}/k_{\\text{on},9}$ is the equilibrium dissociation constant.\n\nSimilarly, for $y_3(t)$: $\\frac{dy_3(t)}{dt} \\approx 0 \\implies k_{\\text{on},3} x(t) c(t) \\approx k_{\\text{off},3} y_3(t)$.\n$$ y_3(t) \\approx \\frac{k_{\\text{on},3}}{k_{\\text{off},3}} x_0 c(t) = \\frac{x_0}{K_3} c(t) $$\nwhere $K_3 = k_{\\text{off},3}/k_{\\text{on},3}$.\n\nNow, we consider the dynamics of the total active caspase pools. The total concentration of active caspase-$9$ is $z_{\\text{total}}(t) = z(t) + y_9(t)$. Its rate of change is:\n$$ \\frac{d z_{\\text{total}}}{dt} = \\frac{d}{dt}(z + y_9) = \\frac{dz}{dt} + \\frac{dy_9}{dt} $$\nFrom the full ODEs in Part 1, summing the equations for $dz/dt$ and $dy_9/dt$ yields:\n$$ \\frac{d z_{\\text{total}}}{dt} = \\left( k_9 a(t) z_p(t) - k_{\\text{on},9} x(t) z(t) + k_{\\text{off},9} y_9(t) \\right) + \\left( k_{\\text{on},9} x(t) z(t) - k_{\\text{off},9} y_9(t) \\right) = k_9 a(t) z_p(t) $$\nApplying the assumptions $a(t) = a_0$ and $z_p(t) \\approx z_0$:\n$$ \\frac{d z_{\\text{total}}}{dt} = k_9 a_0 z_0 $$\nThis is an ODE for $z_{\\text{total}}(t)$ with a constant rate of production. Integrating with respect to time $t$, with initial condition $z_{\\text{total}}(0) = z(0) + y_9(0) = 0 + 0 = 0$:\n$$ z_{\\text{total}}(t) = (k_9 a_0 z_0) t $$\nUsing the pre-equilibrium relation, we have $z_{\\text{total}}(t) = z(t) + \\frac{x_0}{K_9} z(t) = z(t) \\left( 1 + \\frac{x_0}{K_9} \\right)$.\nThus, we can express the free active caspase-$9$ concentration, $z(t)$, as:\n$$ z(t) = \\frac{z_{\\text{total}}(t)}{1 + \\frac{x_0}{K_9}} = \\frac{k_9 a_0 z_0}{1 + \\frac{x_0}{K_9}} t $$\n\nNext, we follow the same procedure for caspase-$3$. The total active caspase-$3$ concentration is $c_{\\text{total}}(t) = c(t) + y_3(t)$. Its rate of change is:\n$$ \\frac{d c_{\\text{total}}}{dt} = \\frac{d}{dt}(c + y_3) = \\frac{dc}{dt} + \\frac{dy_3}{dt} = k_3 z(t) c_p(t) $$\nApplying the assumption $c_p(t) \\approx c_0$:\n$$ \\frac{d c_{\\text{total}}}{dt} = k_3 c_0 z(t) $$\nSubstitute the derived expression for $z(t)$:\n$$ \\frac{d c_{\\text{total}}}{dt} = k_3 c_0 \\left( \\frac{k_9 a_0 z_0}{1 + \\frac{x_0}{K_9}} t \\right) = \\left( \\frac{k_3 k_9 c_0 a_0 z_0}{1 + \\frac{x_0}{K_9}} \\right) t $$\nThis is a separable ODE for $c_{\\text{total}}(t)$. We integrate with respect to time, using the initial condition $c_{\\text{total}}(0) = c(0) + y_3(0) = 0 + 0 = 0$:\n$$ c_{\\text{total}}(t) = \\int_0^t \\left( \\frac{k_3 k_9 c_0 a_0 z_0}{1 + \\frac{x_0}{K_9}} \\right) t' dt' = \\left( \\frac{k_3 k_9 c_0 a_0 z_0}{1 + \\frac{x_0}{K_9}} \\right) \\frac{t^2}{2} $$\nFinally, the problem asks for the free active caspase-$3$ concentration, $c(t)$. Using the pre-equilibrium relation $c_{\\text{total}}(t) = c(t) \\left( 1 + \\frac{x_0}{K_3} \\right)$, we solve for $c(t)$:\n$$ c(t) = \\frac{c_{\\text{total}}(t)}{1 + \\frac{x_0}{K_3}} $$\nSubstituting the expression for $c_{\\text{total}}(t)$ gives the final result:\n$$ c(t) = \\frac{1}{1 + \\frac{x_0}{K_3}} \\left( \\frac{k_3 k_9 c_0 a_0 z_0}{1 + \\frac{x_0}{K_9}} \\frac{t^2}{2} \\right) = \\frac{k_9 k_3 a_0 z_0 c_0 t^2}{2 \\left(1 + \\frac{x_0}{K_9}\\right) \\left(1 + \\frac{x_0}{K_3}\\right)} $$\nThis expression describes the quadratic increase in active caspase-$3$ at short times, modulated by the inhibitory effects of XIAP on both caspase-$9$ and caspase-$3$.", "answer": "$$\n\\boxed{\\frac{k_{9} k_{3} a_{0} z_{0} c_{0} t^{2}}{2 \\left(1 + \\frac{x_{0}}{K_{9}}\\right) \\left(1 + \\frac{x_{0}}{K_{3}}\\right)}}\n$$", "id": "2949701"}]}